With use dating back to the 1800s, suppositories may appear like a deceptively simple, antiquated drug delivery system. However, advances in formulation and product design have transformed them into increasingly sophisticated platforms for therapeutic administration with numerous advantages: Suppositories can provide an alternative to oral administration and support either local or systemic delivery across applications including women’s health, over-the-counter (OTC) therapeutics, and geriatric care.
As activity and competition in the suppository market increase, underestimating these products’ complexity can compromise both quality and commercial viability. In the blog that follows, we’ll discuss why suppositories should be approached as complex drug products and how early formulation choices can impact product stability, dose consistency, scalability, packaging requirements, and production costs.
A Growing Platform for Local and Systemic Delivery
In part, the versatility of suppository drug products has led to an increase in development: They can be administered rectally or vaginally, with the former providing local treatment or delivery of an API across the mucosa for systemic absorption. Vaginal suppositories are more commonly designed for local delivery (though systemic delivery is also possible) for prescription, OTC, and wellness products used for infection, reproductive health, pH management, and probiotics to alter the vaginal microbiome.
These different applications make defining the intended use and site of action a critical first step in product development. The desired clinical endpoint should inform how an API should be released and whether it should enter systemic circulation or remain local.
Formulation is the Foundation of Development
Once the intended use and site of action are defined, formulation must translate those clinical goals into a stable, bioavailable, and manufacturable product. These priorities are interdependent: A formulation may remain stable and provide the intended release profile, but it cannot become commercially viable if it cannot be produced consistently.
Assessing stability, bioavailability, and manufacturability begins with preformulation characterization of the API’s solubility, physical properties, and chemical stability. These data guide the choice between a lipophilic or hydrophilic base and determine whether the API dissolves or remains suspended. Lipid-based systems melt near body temperature, whereas water-soluble bases dissolve in mucosal fluid. In either case, the API must leave the base and enter the surrounding fluid before it can act locally or be absorbed systemically.
When an API suspension is used, particles can settle during mixing, holding, or filling, causing dose variability, particularly for low-dose products. Controlling particle size, viscosity, shear, mixing and hold times, and the interval before filling helps preserve dose uniformity and the intended release profile.
Polymorphisms and Product Performance
Determining whether the API dissolves in the base or remains suspended is just one critical part of base selection. For lipid-based suppositories, the base’s solid-state behavior adds stability and manufacturing challenges.
One of the most important factors is polymorphism: The ability of the same material to form different crystal structures with different melting behavior and stability. Heating and cooling may initially produce a less stable polymorph that transforms into a more stable form during storage. If the API is also polymorphic, interactions between the API’s solid forms and the lipid base add another layer of complexity.
Because these solid-state changes can affect stability, drug release, and manufacturability, evaluate polymorphs early. Techniques like differential scanning calorimetry (DSC) and X-ray diffraction can help characterize thermal transitions and identify different crystal structures, respectively.
The product’s thermal history can also influence its hardness, melting behavior, appearance, release profile, and shelf-life performance. Cooling must therefore be carefully controlled rather than treated as a rapid shock-cooling step, which could favor an undesirable polymorph.
Molded vs. Compressed Suppositories
The impact of thermal history on lipid polymorphism helps illustrate just why manufacturing and formulation need to be closely linked. Suppositories are generally produced by molding or compression, and each approach introduces different thermal histories and hence, process requirements or risks.
Molded products are made by melting the base, dissolving or dispersing the API, filling the molten formulation into molds or preformed packaging cavities, and cooling it until it solidifies. This approach provides formulation flexibility but requires careful control of temperature, mixing, fill weight, and cooling. Excessive heat can degrade ingredients, inadequate mixing can allow suspended particles to settle, and uncontrolled cooling can produce undesirable crystal forms.
Compressed suppositories are produced by blending the API and base as dry materials and compressing the mixture into the required shape. Because the process avoids melting and cooling, it is better suited to heat-sensitive ingredients or formulations susceptible to lipid phase transitions. However, it requires careful control of powder flow, blend uniformity, compressibility, mechanical strength, and patient acceptability.
Therefore, the choice between the two production strategies depends on the API’s properties, desired release profile, and processing requirements. It must also account for how those materials and process conditions will behave when production moves from the laboratory to commercial scale.
Redesign for Scale-Up
Selecting a molded or compressed platform sets the basic manufacturing approach, but scale-up is not linear, where you simply swap out laboratory-scale equipment for equipment that accommodates larger volumes.
For molded suppositories, larger vessels alter heat transfer, mixing, shear, hold time, and sedimentation risk, while manual filling and bench-scale cooling shift to continuous, automated operations. For compressed products, changes in blending, powder flow, compression speed, and compaction force can affect dose uniformity and mechanical strength. In either case, conditions that produced an acceptable laboratory batch may cause degradation, inconsistent doses, or other quality failures at scale.
Development should therefore proceed with commercial scale-up in mind. Moving from laboratory equipment to semi-automatic engineering batches and then fully automated manufacturing lets teams see how the formulation responds to each process and set appropriate controls. Design-of-experiments (DoE) studies can then link material properties and process parameters to product quality, helping define the operating conditions needed for consistent commercial production.
Form-Fill-Seal (FFS) Integrates Manufacturing and Packaging
For molded suppositories, one commercial-scale option is form-fill-seal (FFS), which forms packaging cavities from polymer film and integrates filling, controlled cooling, and sealing on a continuous line. This can improve throughput and consistency but leaves little opportunity to correct variation between steps. Temperature, mixing, transfer, fill accuracy, cooling, line speed, and sealing must therefore function as a coordinated system.
FFS also makes packaging part of product design. Films can be selected to protect light-, oxygen-, moisture-, or temperature-sensitive ingredients. The package should therefore be developed alongside the formulation and process, with its materials matched to ingredient sensitivities and storage requirements. This integrated approach can also support emerging multi-chamber designs.
Commercial Readiness Begins with Early Development
API, base, manufacturing platform, thermal process, and packaging choices all shape performance, scalability, regulatory strategy, and cost. Evaluating them together and early in development can reduce reformulation, scale-up failures, and delays.
At LGM Pharma, we integrate formulation, analytical testing, regulatory strategy, process development, and manufacturing for the molded and compressed suppositories we produce. Early collaboration aligns these disciplines, creating a clearer path from laboratory development through engineering batches to scalable FFS production.
Contact us today to talk to a suppository development and manufacturing specialist and learn what partnering with us looks like.
Frequently Asked Questions
- Are suppositories simple to develop and manufacture?
Not as simple as they look. Base selection, API solubility, polymorphism, and thermal history all affect stability, dose consistency, and release. Underestimating that complexity can compromise both quality and commercial viability. - What is the difference between molded and compressed suppositories?
The main difference is heat. Molded suppositories are made by melting the base, adding the API, and cooling the mixture in molds or packaging cavities. Compressed suppositories are made from a dry blend pressed into shape, which makes them better suited to heat-sensitive ingredients. - How do you choose a suppository base?
It starts with the API. Preformulation data on solubility, physical properties, and chemical stability determine whether a lipophilic base, which melts near body temperature, or a hydrophilic base, which dissolves in mucosal fluid, is the better fit. Those data also show whether the API will dissolve in the base or stay suspended. - Why does polymorphism matter in suppositories?
It can change how the product performs over time. Lipid bases can form different crystal structures, and an unstable form created during cooling may shift during storage. That shift can affect hardness, melting behavior, drug release, and shelf life, so polymorphs should be evaluated early. - Can a lab-scale suppository formulation be scaled up directly?
No. Larger equipment changes heat transfer, mixing, shear, hold times, and sedimentation risk, so conditions that worked at the bench can cause degradation or dose variability at scale. Moving through engineering batches and using design-of-experiments studies helps define controls before commercial production. - What should you look for in a suppository manufacturing partner?
Look for a partner that evaluates formulation, process, and packaging together rather than in sequence. Experience with both molded and compressed platforms, in-house analytical and regulatory support, and a clear path from engineering batches to commercial form-fill-seal production all reduce the risk of reformulation and delays.